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Background Previous studies have examined associations of cardiometabolic factors with 
depression and cognition separately.  
Aim To determine if depressive symptoms mediate the association between cardiometabolic 
factors and cognitive decline in two community studies. 
Methods Data for the analyses were drawn from the Rotterdam Study, Netherlands (n=2940) 
and the Whitehall II Study, United Kingdom (N=4469).  
Results Mediation analyses suggested a direct association between cardiometabolic factors and 
cognitive decline and an indirect association through depression: poorer cardiometabolic status at 
time 1 was associated with a higher level of depressive symptoms at time 2 (standardized 
regression coefficient 0.07 and 0.06 in Rotterdam and Whitehall II, respectively), which, in turn, 
was associated with greater cognitive decline between times 2 and 3 (standardized regression 
coefficient of -0.15 and -0.41, respectively).  
Conclusions Evidence from 2 independent cohort studies suggests an association between 
cardiometabolic dysregulation and cognitive decline and that depressive symptoms tend to 
precede this decline.  
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Cognitive decline is an important public health issue (1). Progressive deterioration of cognitive 
function can affect an individual’s overall health and well-being, including daily self-care 
activities (e.g., dressing, bathing, and housework), as well as the ability to effectively manage 
existing medical conditions and to participate actively in society. 
Increasing evidence suggests that cardiometabolic factors, including central obesity (2), 
dyslipidemia (3), hypertension (4), insulin resistance or diabetes (5), and inflammation (6) might 
accelerate cognitive decline in midlife and at older ages. Similarly, the metabolic syndrome, a 
cluster of metabolic abnormalities that increase cardiovascular risk, has been associated with 
cognitive decline in prospective cohort studies (7).   
Emerging evidence suggests that the association between cardiometabolic dysregulation and 
cognitive decline may include indirect pathways via depressive symptoms (8). Specifically, a 
meta-analysis by Pan et al. (9) found evidence for a bidirectional association between metabolic 
syndrome and depression. There is also considerable evidence linking depression with cognitive 
impairment. Meta-analyses suggest that depression at older ages may be a risk factor for 
Alzheimer’s disease (10) and have found moderate impairment in executive function, memory 
and attention in individuals with depression relative to controls (11). However, recurrent or 
increasing levels of depressive symptoms may also be a prodrome of dementia (12).  
We hypothesise that depressive symptoms are one pathway that links cardiometabolic factors to 
cognitive decline. Given that previous studies have examined associations of cardiometabolic 
factors with depression and cognitive functioning separately, the temporal relations between 
these factors are unknown. Using data from two longitudinal community-based samples of adults 
in the Netherlands (Rotterdam Study) and the UK (Whitehall II Study), this study evaluated if 
depressive symptoms mediate the association between cardiometabolic factors and cognitive 
decline while controlling for other risk factors.  
 
Method 
Design/setting and participants 
Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study of adults in Rotterdam, 
Netherlands. More details are provided elsewhere (13). Briefly, in 1990 all inhabitants aged 55 
years and older living in a catchment area in Rotterdam were invited to participate. A total of 
7983 (78%) individuals agreed to participate. The initial cohort was expanded by 3011 
individuals aged 55 years and older in 2000. This study used the third data wave of the first 
cohort (1997–99) and the first wave of the expanded cohort (2000–01) as baseline in the present 
study. All participants underwent home interviews and an extensive set of examinations in a 
research center at baseline and after approximately 5 and 12 years (2002-04 and 2009-11; 
original cohort) and after approximately 4 and 11 years (2004-05 and 2011-12; extension 
cohort). The Rotterdam Study has been approved by a medical ethics committee, in accordance 
with the Population Screening Act: Rotterdam Study, executed by the Netherlands Ministry of 
Health, Welfare and Sports. All participants in the present analysis provided written informed 
consent.  
Depression was assessed using a validated Dutch 20-item version of the Centre for 
Epidemiologic Studies Depression  (CES-D) scale (14), which measures self-reported frequency 
of depressive symptoms experienced during the past week. The CES-D are scored on a four-
point Likert scale, ranging from ‘rarely or none of the time’ to ‘most or all of the time’. 
Cognitive function was assessed twice (second and third wave) at separate center visits (15). The 
test battery included the Stroop test (16), letter-digit substitution task (LDST) (15), verbal 
fluency test (VF) (17), 15-word verbal learning test (15-WLT) (18), and the Purdue pegboard test 
(19). Higher scores on each test indicate a better performance, except for the Stroop test in which 
a higher score indicates a worse performance. Scores for the Stroop test were thus inverted. All 
tests were scored so that higher scores indicated better cognitive function.  
Cardiometabolic dysregulation was defined using the facets of the metabolic syndrome (20): 
elevated blood pressure (BP >130/85mmHg or use of anti-hypertensive medication), impaired 
glycaemic control (fasting blood glucose concentration greater than 5.6 mmol/L (38 mmol/mol) 
or diagnosed type 2 diabetes), low high-density lipoprotein cholesterol (< 1.03 mmol/L in men 
and <1.30 mmol/L in women), elevated triglycerides (> 1.7 mmol/L) and central obesity (waist 
circumference ≥ 102 cm (men), ≥ 88 cm (women)). Systemic inflammation was added as an 
additional risk factor (C-reactive protein > 3 mg/L). These measures were collected during 
research centre visits. 
Level of education was categorized into low (primary education), medium (intermediate general 
education) and high (higher vocational education or university) levels. Smoking status was 
assessed by interview and categorized as smoker (current smoker) and non-smoker (never or 
former smoker). Physical activity levels were assessed with an adapted version of the Zutphen 
Physical Activity Questionnaire, which assigns a metabolic equivalent of task  (MET) to all 
activities (21). Participants were classified into three groups of physical activity as low physical 
activity (<10 Met-hours per week); medium physical activity (between 10 and 50 Met-hours per 
week) and high physical activity (>50 Met-hours per week). 
 
The Whitehall II Study 
The Whitehall II Study is a prospective cohort study of London based office staff working in 20 
civil service departments. More details are provided elsewhere (22). Briefly, a total of 10,308 
individuals (73% response rate) aged 35 to 55 years were recruited between 1985 and 1988. Ten 
follow-up assessments were conducted; participants were assessed approximately every two to 
three years. A clinical assessment was conducted every second phase. Informed consent was 
obtained from all participants, and the University College London Medical School Committee on 
the Ethics of Human Research approved the protocol.  
Wave 5 (1997-1999) was used as baseline for our analyses where the age range was between 45 
and 69 years. Cardiometabolic factors were categorized as in the Rotterdam Study. Missing waist 
circumference was substituted with body mass index (BMI >30 kg/m2 for obesity). Depression 
was assessed using the 20-item Centre for Epidemiologic Studies Depression (CES-D) scale 
(14), which was administered at wave 7 for the first time. Therefore, we have used the four item 
depression subscale of the 30-item General Health Questionnaire (GHQ) (23) to control for 
depressive symptoms at baseline. 
Educational attainment was grouped into three levels (no formal education or lower secondary 
education, intermediate education, and higher degree). Ethnicity was drawn from wave 1 and 
categorised as caucasian/non-caucasian. Smoking status was assessed by interview and coded as 
never, former and current. Intensity of physical activity was assessed via questionnaires. 
Participants were asked about the frequency and duration of their participation in “mildly 
energetic”, “moderately energetic” and “vigorous” physical activity. The measures were 
combined and categorized high, medium, and low activity. 
Cognitive function was assessed by four standard tasks at waves 5,7, and 9. Short-term verbal 
memory was assessed with a 20-word free recall test. The Alice Heim 4-I (AH4-I) was used to 
assess inductive reasoning. Phonemic and semantic verbal fluency was assessed via “S” words 
for phonemic fluency and via “animal” words for the semantic fluency. More details can be 
found elsewhere (24). The most recent waves (i.e., 7 and 9) were used in the present study. 
 
Statistical analyses 
Structural equation modelling was used to examine a potential mediating role of depression in 
the association between cardiometabolic dysregulation and cognitive decline. Mediation analyses 
requires a temporal relationship between exposure (cardiometabolic dysregulation, wave 1), 
mediator (depressive symptoms, wave 2) and outcome (cognitive decline, wave 3). Therefore, 
longitudinal data from three waves was used for each cohort (25). Structural equation models are 
an extension of regression analysis that can handle measurement error, latent variables, and 
relationships among latent and observed variables. Latent variables summarize the information 
from observed variables and account for measurement error and the individual contribution of 
each measure (26). Elevated blood pressure, impaired glycaemic control, low high-density 
lipoprotein cholesterol, elevated triglycerides, central obesity and systemic inflammation were 
used as indicators for the baseline latent cardiometabolic dysregulation measure. The cognitive 
tests in each study were used as indicators for a general cognitive function (g-factor).  
Change in cognitive function between two assessments was modeled using a latent change score 
approach (27). In these models, a latent difference score is created by a distinct latent construct 
representing the difference between the two cognitive g- factors. Briefly, the model constrains 
the association between the first latent score and the second latent score to 1, such that any 
variance in the second latent score that was not explained by the first latent score would be 
accounted for by the latent change score for a given participant. The conceptual framework is 
shown in Figure 1: first, two latent constructs representing the cognitive g-factors at time 2 and 
time 3 were created. Second, a latent change score (cognitive decline) was constructed so that the 
cognitive g-factor at time 3 is considered to be the sum of the cognitive g-factor at time 2 plus 
the latent change score. Regression coefficients between the time 2 and time 3 cognitive 
functioning g-factors were constrained to 1, and regression coefficients between the time 3 
cognitive functioning g-factor and the latent change score was also constrained to 1 so that the 
latent change score represented the nature of the change in cognitive functioning g-factors from 
time 2 to time 3. The cognitive g-factor at time 2 was standardized to a mean of 0 and a SD of 1 
so that higher scores indicate better cognitive functioning. Third, the latent change score was 
correlated with the cognitive functioning g-factors from time 2 to account for individual changes 
over time that are associated with the initial cognitive functioning score at time point 2. A 
negative change score indicates a cognitive decline. Depressive symptoms at baseline were 
included in all models to account for previous depression symptoms. In a final step, associations 
between cardiometabolic risk factor at time 1 (latent variable), depression at time 2 (manifest 
variable) and cognitive change (latent variable) are modeled using a regression framework. We 
controlled for sex, age, education, ethnicity, smoking and physical activity in our analyses. In the 
Rotterdam Study, cohort was also controlled for. Depressive symptoms at baseline were included 
in all models to account for previous depression symptoms. In the Rotterdam Study, cohort 
source was also controlled for.  
Depression was modelled as a mediator between cardiometabolic dysregulation and cognitive 
decline. A direct association between the metabolic risk factor at time 1 and cognitive decline 
(time 2 to 3) was estimated, as well as an indirect association through depression at time 2 (e.g., 
metabolic risk factor at time 1 predicts depression at time 2, which in turn predicts cognitive 
decline from time 2 to 3). Indirect association coefficients were calculated by multiplying the 
standardized coefficients for the paths from the predictor to the mediator (e.g., metabolic risk 
factor to depression) and from the mediator (depression) to the outcome (cognitive decline) (28).      
The general goodness of fit of each model was evaluated using the Comparative Fit Index (CFI) 
and the Root Mean Square Error of Approximation (RMSEA). A CFI of 0.90 or more and 
RMSEA of 0.08 or lower indicates adequate fit (29). 
Multiple imputed values for the missing data from the variables used in the analysis were 
generated (PROC MI in SAS). In sensitivity analyses, analyses were rerun without imputed 
values for missing covariates.  
All analyses were conducted with SAS (version 9.4) and MPlus (Version 7.4). Because observed 
cardiometabolic indicators were dichotomous, the weighted least squares estimator with a 
diagonal weight matrix, robust standard errors and a mean- and variance-adjusted χ2 test statistic  
(WLSMV) and theta parameterization (30) were used for parameter estimation in MPlus. 
 
Results 
Findings from the Rotterdam Study 
A total of 2940 individuals participated in all three assessments of the Rotterdam Study and had 
data on cardiometabolic factors, depression and cognitive functioning (see flow chart for sample 
selection in online Figure OF1). Mean ages at baseline, first and second follow-ups were 65.0 
years (SD=5.9), 69.3 years (SD=6.1) and 75.8 years (SD=6.1), respectively. There were more 
women than men in the sample (57 %). Table 1 presents baseline characteristics of participants. 
There were sociodemographic and health differences at baseline between those who participated 
in all three assessments and those who participated only in one or two assessments; individuals 
who participated at all assessments were younger (65 years vs. 73 years), more likely to have a 
high educational level (16.0% vs. 10.6%), more likely to have a high physical activity level 
(74.6% vs 59.1%), less likely to have elevated depressive symptoms (5.8 % vs. 15.3%), and were 
more likely to have no metabolic risk factors (15.4% vs. 9.6%). See online Figure 1 for a flow 
chart of the sample selection. 
 
Table 1 here 
Table 2 here 
 
Mean depression scores increased between the first (M=3.9, SD= 6.2) and second assessment 
(M=5.3, SD= 6.9) (p<0.001). Individuals with no metabolic risk factor had lower mean 
depression scores at the second assessment (M=4.5, SD=5.7) than those with one or two 
metabolic risk factors (M=5.2, SD=6.8) and those with three or more metabolic risk factors 
(M=5.7, SD=7.5) (test for a linear trend across the cardiometabolic risk factors groups: 
F(1,2937)=13.4, p<0.001).   
Cognitive decline was observed between the second and third assessment on all cognitive 
functioning subtests: the effect sizes of change (difference between first and second cognitive 
functioning subtest score, divided by SD of the first score) were 0.41, 0.18, 0.39, 0.12 and 0.50 
for the letter-digit substitution task, verbal fluency test, Stroop test, 15-word verbal learning test, 
and Purdue pegboard test, respectively. Table 2 describes the associations between the number of 
cardiometabolic risk factors at baseline and change in cognitive functioning (g-factors controlled 
for age and sex). Individuals with no cardiometabolic risk factors had the highest cognitive 
functioning scores at time 2 and time 3 compared to those with or one more cardiometabolic risk 
factors. Individuals with no cardiometabolic risk factors had the highest cognitive functioning 
scores at time 2 and time 3 while individuals with three or more cardiometabolic risk factors had 
the lowest cognitive functioning scores at time 2 and time 3. The largest cognitive decline was 
observed for those with three or more cardiometabolic risk factors.  
 
Figure 1 here 
Figure 2 here 
 
Results of the mediation analyses are presented in Figure 1. The model fit was acceptable 
(CFI=0.933, RMSEA=0.041). Results show that a poorer cardiometabolic status at baseline was 
associated with greater cognitive decline, after controlling for age, sex, education, ethnicity, 
cohort, smoking and physical activity. There was a direct association from the latent variable 
cardiometabolic risk factor to cognitive decline (standardized regression coefficient of -0.43, 
p<0.001) and an indirect association through depression; poorer cardiometabolic status at 
baseline was associated with a higher level of depressive symptoms at time 2 (standardized 
regression coefficient of 0.07, p<0.001) which in turn was associated with cognitive decline 
(standardized regression coefficient of -0.15, p<0.001).   
The indirect association coefficients were small but significant: -0.011 (95 % CI: -0.002 to   
-0.020), suggesting that depression partially mediated the association between cardiometabolic 
status and cognitive decline.  
 
Findings from the Whitehall II Study 
A total of 4469 individuals participated in waves 5, 7 and 9 of the Whitehall II Study and had 
data on cardiometabolic factors, depression and cognitive functioning. The mean age at baseline 
(wave 5, M=55.2, SD=5.9) was almost 10 years lower compared to the Rotterdam Study and 
there were almost three times more men than women in this cohort. Mean ages at wave 7 and 9 
were 61 (SD=6.0) years and 66 (SD=6.0) years, respectively.  
Table 1 shows sociodemographic and clinical characteristics of participants at wave 5 (the 
baseline). Those who participated in all three assessments were more often male  (73.9% vs. 
63.3%), more likely to be younger  (55 years vs. 57 years), more likely to have a high 
educational level  (38.6% vs. 30.7%), more likely to have a high physical activity level (56.5% 
vs. 47.8%), less likely to have elevated depressive symptoms  (16.1% vs. 20.5%), and were more 
likely to have no metabolic risk factors  (31.7% vs. 23.5%) than those who participated only in 
wave 5. Individuals with no metabolic risk factor had lower mean depression scores at the 
second assessment (M=7.7, SD=7.5) then those with three or more metabolic risk factors 
(M=8.4, SD=7.8). See online Figure 1 for a flow chart of the sample selection. 
 Cognitive decline was observed between the second and third assessment on all cognitive 
functioning subtests: the effect sizes were 0.07, 0.29, 0.16, and 0.14 for the Alice Heim 4-I task, 
Short-term verbal memory task, phonemic and semantic verbal fluency tasks, respectively. 
Associations between the number of cardiometabolic risk factors at baseline and the change in 
cognitive functioning (g-factors controlled for age and sex) are presented in Table 2. 
Associations were similar as in the Rotterdam Study, although changes in cognitive functioning 
g-factors were smaller. Individuals with no cardiometabolic risk factors had the highest cognitive 
functioning scores at time 2 and time 3 compared to those with one or more cardiometabolic risk 
factors.  
The mediation analyses (Figure 2) also suggested a potential mediating effect of depression in 
the association between metabolic risk factors and cognitive decline. Model fit was acceptable 
(CFI=0.917, RMSEA=0.049). There was a direct association from the latent variable 
cardiometabolic risk factor to cognitive decline (standardized regression coefficient of -0.44, 
p<0.001) and an indirect association through depression: poorer cardiometabolic status at 
baseline was associated with a higher level of depressive symptoms at time 2 (standardized 
regression coefficient of 0.06, p=0.003) which, in turn, was associated with cognitive decline 
(standardized regression coefficient of -0.40, p<0.001).  The indirect association coefficient was 
-0.023 (95 % CI: -0.005 to -0.041), which if anything, was higher than in the Rotterdam Study.  
 
Discussion 
This study evaluated temporal associations between cardiometabolic risk factors, depressive 
symptoms and change in cognitive function in two community studies of individuals aged 45 
years and above in the Netherlands and the UK. Evidence from both studies suggest a direct 
association between cardiometabolic risk factors and cognitive decline and an indirect 
association through depressive symptoms: cardiometabolic risk factors at time 1 predicted 
depressive symptoms at time 2 (4 to 5 years later), which, in turn, predicted cognitive decline 
from time 2 to time 3 (4 to 6 years later). 
These results suggest that depression might be one potential pathway through which 
cardiometabolic dysfunction is associated with cognitive decline. To our knowledge, this is the 
first study that simultaneously estimated longitudinal associations between cardiometabolic 
functioning, depressive symptoms and change in cognitive functioning. The congruence of the 
results from the Rotterdam cohort with those from the Whitehall II cohort, which is comprised of 
persons 10-years younger, suggests that the mediating role of depression apply to elderly 
populations as well as middle aged adults who are not yet experiencing accelerated cognitive 
decline.   
The main strength of this study is the repeated measurement of cognitive function using 
validated cognitive batteries, as well as the availability depression assessments and 
cardiometabolic variables in two large population-based samples. Strengths of the analysis 
include a structural equation modeling approach that permitted the modeling of the dynamic 
relationship between cardiometabolic factors, depressive symptoms and change in cognitive 
function. This approach accounted for measurement error by including latent variables for 
cardiometabolic functioning and cognitive functioning.  A latent change score approach for the 
evaluation of cognitive decline is a more flexible approach than a simple difference score 
approach because latent change score methods separate out the portion of change that is 
correlated with the initial measurement and thereby removing a source of unreliability of a 
simple change score.  
There are also several study limitations. Depressive symptoms were assessed using a self-report 
scale, and not diagnostic interviews that assessed depressive symptoms experienced in the past 
week and does not account for treatment of depression and history of depression. The overall 
level of depression was low, given that we examined nonclinical cohorts. In addition, lifestyle-
related behaviours were also assessed by self-report, and thus may be subject to some bias. 
Cognitive functioning was only assessed at the second and third assessment. Therefore, we were 
not able to control for baseline cognitive functioning. 
Attrition is an expected issue in large elderly population cohorts. Indeed, there were substantial 
sociodemographic and clinical differences between those who participated in all three 
assessments and those who did not, indicating that individuals with a better cardiometabolic 
functioning and a lower level of depressive symptoms were included in our cohort. This might 
have resulted in an underestimation of the underlying associations.  
The time interval (4 to 5 years) between our single measurement of cardiometabolic functioning 
and the measurement of cognitive functioning could also be considered as a limitation. For 
example, Akbaraly et al. have demonstrated that only persistent metabolic syndrome was 
associated with lower cognitive performance in late midlife (24). Cardiometabolic functioning 
might have changed after the assessment due to clinical treatment or change of lifestyle-related 
behaviors. Finally, the applicability to other ethnic groups may be limited since the majority of 
the participants in the present study were white. 
Our findings are consistent with previous prospective studies have focused on comorbid 
depression as a risk a risk factor for cognitive decline or dementia in people with diabetes, a 
clinical form of cardiometabolic dysregulation. A recent systematic review on the association 
between depressive symptoms and cognitive functioning in people with diabetes found evidence 
that the presence of depressive symptoms in persons with diabetes was associated with poorer 
cognitive outcomes (31). Sullivan et al. (32) described an interaction between depression and 
diabetes on cognitive outcomes in the Action to Control Cardiovascular Risk in Diabetes-
Memory in Diabetes (ACCORD-MIND) trial; patients with type 2 diabetes and comorbid 
depression were at higher risk for cognitive decline than those with type 2 diabetes without 
depression. Similar results have been reported from two studies using administrative databases 
(33, 34). Our study adds to this evidence by considering temporality and suggesting that 
depression might explain some of the association between metabolic factors and cognitive 
decline (partial mediation). Management of cardiometabolic risk factors requires patient 
engagement. Depression is associated with poorer self-care behaviors (e.g., following a healthy 
diet, not smoking, engaging in exercise and medication adherence), which could worsen the 
management of the metabolic risk factors course and increase the risk of cognitive decline 
through a long-term exposure to metabolic risk factors (24).  
Cardiometabolic dysregulations and depression also share common pathophysiologic 
mechanisms, including dysregulation of the hypothalamic-pituitary-adrenocortical (HPA) axis 
(35)). The co-occurrence of both conditions might adversely impact both conditions, which can 
in turn result in several metabolic dysregulations and might amplify the risk of cognitive decline 
(36). Vogelzangs et al.(37) have shown that metabolic dysregulations predicted a more chronic 
course of depressive disorders. Recurrent or chronic depressive symptoms are associated with 
prolonged exposure to psychosocial and other life stresses, which can wear and tear different 
circulatory, inflammatory, immune and psychological regulatory systems (38, 39) and increase 
allostatic load (38). Allostatic load has been associated with cognitive decline in population 
studies (40). Liu et al. (41) concluded in a recent review that several other overlapping 
physiological mechanisms in addition to HPA axis disturbances may explain the association of 
metabolic dysfunction with worse cognition in individuals with depression, including 
abnormalities in brain-derived neurotrophic factor signaling, adipose-derived hormones, insulin 
signalling, inflammatory cytokines, and oxidative and nitrosative stress.  
In conclusion, our findings show that people with metabolic dysregulation are at increased risk 
of cognitive decline and that depressive symptoms may partially mediate this decline. This has 
important implications for investigating the pathways which could link metabolic dysregulation 
and increased risk of cognitive decline. For adequate prevention of cognitive decline both 
cardiometabolic and mental health should play a key role. 
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Table 1: Baseline characteristics of the Rotterdam Study cohort and the Whitehall II Study 
cohort 
 Rotterdam Study 
(n=2940) 
Whitehall II Study 
(n=4635) 
 













Educational level, % 
  Low 
  Intermediate 

























Physical activity, % 
  Low 
  Medium 










Cardiometabolic risk factors* 
  Hypertension, %  
  Impaired glycaemic control, %  
  Low high-density  
  Lipoprotein cholesterol, % 
  Elevated triglycerides, %   
  Elevated CRP levels, %     


















  Depression 
  CES-D summary score 
     Elevated depressive symp., % 
  GHQ depression subscale 
      summary score 












Table 2: Association between cardiometabolic risk factors and depression and cognitive functioning in the Rotterdam Study cohort 
and the Whitehall II Study cohort 
 Rotterdam Study 
 





































0    
 








1166 -0.16 (0.86) -0.81 (1.09) -0.65 (0.31) 777 -0.14 (1.02) -0.34 (1.06) -0.20 (0.11) 
 
Note. A g-factor for cognitive functioning was computed from the five cognitive function tests using confirmatory factor analyses as 
shown in Figure 1. Scores were standardized to have standard deviation of 1 (time 2 and 3) and a mean of 0 (time 2) so that negative 
scores indicate poorer cognitive function. A test for a linear trend across the cardiometabolic risk factors groups indicated a 
statistically significant decrease of g-factor scores across groups (Rotterdam Study: F(1,2937)=49.6, p<0.001; Whitehall II Study: 




Figure 1: Depressive symptoms as a potential mediator between cardiometabolic risk factors at 





Figure 1 legend 
Rectangles represent measured variables, and circles represent latent constructs. Standardized 
regression coefficients are presented. Italicized path coefficients reflect constraints imposed on 
the model. The second assessment (T2) was conducted approximately 4-5 years after baseline 
while the third assessment (T3) was conducted approximately 10-11 years after baseline.  
The variable "cardiometabolic risk factors" is standardized so that a positive score indicates 
higher risk. The variable “cognitive decline” is standardized so that positive scores indicate 







Figure 2: Depressive symptoms as a potential mediator between cardiometabolic risk factors at 




Figure 2 legend 
Rectangles represent measured variables, and circles represent latent constructs. Standardized 
regression coefficients are presented (unstandardized estimates shown in parentheses). Italicized 
path coefficients reflect constraints imposed on the model. The third (T3) and fifth (T5) 
assessment were conducted approximately 4 and 8 years after baseline, respectively.  
The variable "cardiometabolic risk factors" is standardized so that a positive score indicates 
higher risk. The variable “cognitive decline” is standardized so that positive scores indicate 
cognitive improvement from T3 to T5 and negative scores indicate cognitive decline from T3 to 
T5.  
 
 
